# Nanopath

> Amplification-free plasmonic molecular diagnostics aiming for 15-minute women's-health testing.

## Why it is interesting

November 10, 2026 financing is $25M including $2M non-dilutive grant capital, not $25M equity. Its first vaginitis assay is still under development and not FDA-cleared; the funding supports a proposed 510(k) clinical study and manufacturing readiness.

## Profile

- **Latest funding:** Series B financing package (includes $2M non-dilutive grants) — $25M total package (~$23M non-grant portion inferred) (November 10, 2026)
- **Latest known valuation:** Undisclosed (November 10, 2026)
- **Total disclosed equity funding:** $14M
- **Stage:** series-b
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-11
- **Latest funding investors:** Norwest, Medtech Convergence Fund (SV Health Investors), Labcorp Venture Fund, Elderberry Ventures, GingerBread Capital, Alumni Ventures

## Key facts

- Nov 10, 2026 issuer describes $25M Series B financing package including $2M non-dilutive grants; approximately $23M is implied non-grant finance, but the precise share terms are not public.
- August 9, 2022 $10M Series A led by Norwest and SV Health Investors' Medtech Convergence Fund.
- May 21, 2024 separate NIH/NSF SBIR grants $4M, not venture equity. The 2026 company-reported more-than-$46M lifetime financing mixes financing types and cannot be used as equity-only total.
- Lead vaginitis assay explicitly not FDA cleared or approved as of Nov 10, 2026, despite work toward a 510(k) study.

## Funding history

- Series B financing package (includes $2M non-dilutive grants) · $25M total package (~$23M non-grant portion inferred) · November 10, 2026
  Source: https://www.prnewswire.com/news-releases/nanopath-announces-25-million-series-b-financing-to-advance-molecular-testing-for-womens-health-302934485.html
- NIH/NSF SBIR grants (non-dilutive, NOT Series A extension) · $4M · May 21, 2024
  Source: https://www.prnewswire.com/news-releases/nanopath-receives-4-million-in-grants-from-national-institutes-of-health-and-national-science-foundation-302150413.html
- Series A · $10M · August 9, 2022
  Source: https://www.prnewswire.com/news-releases/nanopath-secures-10-million-in-series-a-funding-to-develop-and-commercialize-point-of-care-diagnostics-for-womens-health-301602364.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 11, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/nanopath